ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 13, 2017, Chuck Olson tendered his letter of resignation from the role of Senior Vice President, Chief Technology Officer, effective July 13, 2017. Dr. Olson will continue to be available to the Company in an advisory role with respect to the Company’s manufacturing strategy.
On July 13, 2017, Dr. Renee Martin, Ph.D., who joined the Company in March 2010 and is currently serving as the Company’s Senior Vice President, Medical Science, will assume functional leadership for the Company’s manufacturing strategy which complements and expands her background of scientific research.
About ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH)
Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.
